These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 22390555)

  • 21. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Octreotide for acromegaly treatment: a reappraisal.
    Giustina A; Karamouzis I; Patelli I; Mazziotti G
    Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event.
    Casagrande A; Bronstein MD; Jallad RS; Moraes AB; Elias PC; Castro M; Czepielewski MA; Boschi A; Ribeiro-Oliveira A; Schweizer JR; Vilar L; Nazato DM; Gadelha MR; Abucham J;
    Neuroendocrinology; 2017; 104(3):273-279. PubMed ID: 27161443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR
    Delemer B; Nguyen-Tan-Hon T; Coriat R; Smith D; Schillo F; Raingeard I; Sobhani I; Etienne PL; Decoudier B; Bisot-Locard S; Santos A; Raverot G; Cadiot G
    Adv Ther; 2020 Sep; 37(9):3901-3915. PubMed ID: 32683667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
    Tiberg F; Roberts J; Cervin C; Johnsson M; Sarp S; Tripathi AP; Linden M
    Br J Clin Pharmacol; 2015 Sep; 80(3):460-72. PubMed ID: 26076191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis on the effects of octreotide on tumor mass in acromegaly.
    Giustina A; Mazziotti G; Torri V; Spinello M; Floriani I; Melmed S
    PLoS One; 2012; 7(5):e36411. PubMed ID: 22574156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octreotide LAR: safety and tolerability issues.
    Bornschein J; Drozdov I; Malfertheiner P
    Expert Opin Drug Saf; 2009 Nov; 8(6):755-68. PubMed ID: 19998528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cautionary note on generic depot octreotide.
    Gallardo W; de Las Casas MI; Mercado M
    Pituitary; 2015 Aug; 18(4):581-2. PubMed ID: 25064084
    [No Abstract]   [Full Text] [Related]  

  • 29. Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update.
    Arregger AL; Cardoso EM; Sandoval OB; Monardes Tumilasci EG; Sanchez R; Contreras LN
    Am J Ther; 2014; 21(4):e110-6. PubMed ID: 22820717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Divergent effects of octreotide on glucose tolerance in patients with acromegaly.
    Hizuka N
    Intern Med; 1997 May; 36(5):319-20. PubMed ID: 9213165
    [No Abstract]   [Full Text] [Related]  

  • 31. Review of a home nursing injection service: SHINE.
    Willenberg V; Bamblett M; Cummins M; Hoberg D
    Aust Nurs Midwifery J; 2014 Dec; 22(6):30-3. PubMed ID: 29236425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary medical therapy for acromegaly.
    Freda PU; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3031-3. PubMed ID: 9745396
    [No Abstract]   [Full Text] [Related]  

  • 33. Sandostatin (octreotide acetate).
    Claussen D
    Gastroenterol Nurs; 1992 Dec; 15(3):122-4. PubMed ID: 1472557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Octreotide (sandostatin, sandoz).
    Mac Connachie AM
    Intensive Crit Care Nurs; 1996 Apr; 12(2):120-1. PubMed ID: 8845623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
    Petersenn S; Houchard A; Sert C; Caron PJ;
    Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment.
    Nomoto H; Kameda H; Nakamura A; Tsuchida K; Nagai S; Atsumi T; Miyoshi H
    Front Endocrinol (Lausanne); 2019; 10():131. PubMed ID: 30881346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preservation of blood glucose homeostasis in slow-senescing somatotrophism-deficient mice subjected to intermittent fasting begun at middle or old age.
    Arum O; Saleh JK; Boparai RK; Kopchick JJ; Khardori RK; Bartke A
    Age (Dordr); 2014 Jun; 36(3):9651. PubMed ID: 24789008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide receptor targeting in cancer: the somatostatin paradigm.
    Barbieri F; Bajetto A; Pattarozzi A; Gatti M; Würth R; Thellung S; Corsaro A; Villa V; Nizzari M; Florio T
    Int J Pept; 2013; 2013():926295. PubMed ID: 23476673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Octreotide long-acting repeatable for acromegaly.
    Cozzi R; Attanasio R
    Expert Rev Clin Pharmacol; 2012 Mar; 5(2):125-43. PubMed ID: 22390555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.